



Areacor Therapeutics plc
("Areacor" or the "Company")

ARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER

- ***Collaboration will leverage Arestat™ to develop a novel formulation of partner's proprietary product with enhanced properties***
- ***Work will be fully funded by partner***

Cambridge, UK, 26 March 2025: Areacor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has signed a formulation study agreement with a major global pharmaceutical partner.

Under the terms of the agreement, Areacor will use its proprietary formulation technology platform, Arestat™, to develop a novel formulation of the partner's proprietary product with enhanced properties. The partner company will fully fund the formulation work with the potential for future license opportunities to follow.

Sarah Howell, Chief Executive Officer of Areacor, said: "Areacor continues to partner with the world's leading pharmaceutical companies, which is testament to our leadership position in the field of drug delivery and formulation innovation and further validates the potential of our proprietary technology platform, Arestat™ to enable enhanced formulations of partners' proprietary products which would otherwise be unachievable."

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

For more information, please contact:

Areacor Therapeutics plc
Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer

www.arecor.com
Tel: +44 (0) 1223 426060
Email: info@arecor.com

Tel: +44 (0) 1223 426060
Email: info@arecor.com



Singer Capital Markets Advisory LLP (NOMAD and Broker)

Phil Davies, Sam Butcher

Tel: +44 (0) 20 7496 3000

ICR Healthcare

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@icrhealthcare.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com